A Phase 2a Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractor

Administered By

Awarded By

Contributors

Start/End

  • January 23, 2019 - July 31, 2023